Zanganeh Maky's Form 4/A amendment
AmendedSummit Therapeutics Inc. (SMMT) · filed Mar 13, 2023
- Accession no.
- 0001387131-23-003381
- Filed
- Mar 13, 2023
- Trade date
- Mar 8, 2023
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Mar 8, 2023
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market purchases total $25.5M. It was filed 5 days after the trade.
This amendment replaces 0001599298-23-000028 (filed Mar 8, 2023).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Zanganeh MakyCIK 0001507650 | Director, Officer (Co-CEO & President) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 8, 2023 | Common Stock | PPurchaseAcquired | +804,672 | $1.05 | +$844,905.6 | 1,178,529 | Indirect | |
| Mar 8, 2023 | Common Stock | PPurchaseAcquired | +16,778,415 | $1.05 | +$17,617,335.75 | 24,573,798 | Indirect | |
| Mar 8, 2023 | Common Stock | PPurchaseAcquired | +6,748,629 | $1.05 | +$7,086,060.45 | 9,884,095 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.